# Micheli Bevilacqua

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/micheli-bevilacqua/

## Facts

| Field | Value |
| --- | --- |
| Citations | 377 |
| Field | Dialysis and Renal Disease Management |
| h-index | 9 |
| i10-index | 9 |
| Last Known Institution | University of British Columbia |
| OpenAlex ID | https://openalex.org/A5085325427 |
| ORCID iD | 0000-0001-8321-7413 |
| Works | 31 |

## Researcher papers

- [Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial](https://scholariq.org/papers/impact-of-primary-kidney-disease-on-the-effects-of-empagliflozin-in-patients/)
- [Evaluation of A 12-Month Pilot of Long-Term and Temporary Assisted Peritoneal Dialysis](https://scholariq.org/papers/evaluation-of-a-12-month-pilot-of-long-term-and-temporary-assisted-peritoneal/)
- [Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/updated-canadian-expert-consensus-on-assessing-risk-of-disease-progression-and/)
- [Long-term effect of COVID-19 infection on kidney function among COVID-19 patients followed in post-COVID-19 recovery clinics in British Columbia, Canada](https://scholariq.org/papers/long-term-effect-of-covid-19-infection-on-kidney-function-among-covid-19/)
- [Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/assessing-risk-of-disease-progression-and-pharmacological-management-of/)
- [Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder](https://scholariq.org/papers/canadian-society-of-nephrology-commentary-on-the-kidney-disease-improving-global/)
- [CT of Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: Accuracy, Reproducibility, and Radiation Dose](https://scholariq.org/papers/ct-of-kidney-volume-in-autosomal-dominant-polycystic-kidney-disease-accuracy/)
- [Kidney Failure Risk Equation in vascular access planning: a population-based study supporting value in decision making](https://scholariq.org/papers/kidney-failure-risk-equation-in-vascular-access-planning-a-population-based/)
- [Implications of Implementing the 2021 CKD-EPI Equation Without Race on Managing Patients With Kidney Disease in British Columbia, Canada](https://scholariq.org/papers/implications-of-implementing-the-2021-ckd-epi-equation-without-race-on-managing/)
- [Evaluation and outcomes of a 5-year assisted peritoneal dialysis program](https://scholariq.org/papers/evaluation-and-outcomes-of-a-5-year-assisted-peritoneal-dialysis-program/)
- [Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Prescribed SGLT2 Inhibitors in British Columbia: A Single-Arm Retrospective Cohort Study](https://scholariq.org/papers/outcomes-of-patients-with-autosomal-dominant-polycystic-kidney-disease/)

## Researcher topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Genetic and Kidney Cyst Diseases](https://scholariq.org/topics/genetic-and-kidney-cyst-diseases/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Pediatric Urology and Nephrology Studies](https://scholariq.org/topics/pediatric-urology-and-nephrology-studies/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

## Researcher university

- [University of British Columbia](https://scholariq.org/institutions/university-of-british-columbia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.